Telehealth company Hims & Hers began offering a compounded version of Novo Nordisk’s newly approved Wegovy oral formulation, prompting public rebukes and legal threats from Novo and enforcement warnings from FDA leadership. FDA Commissioner Marty Makary signaled the agency would act against companies mass‑marketing non‑approved copies, and Novo Nordisk has threatened litigation over what it calls an "unapproved, inauthentic" product. The friction spotlights tensions around compounding, telehealth distribution, and rapid commercial demand for GLP‑1s. Industry and regulators face pressure to respond quickly: manufacturers argue compounding undermines safety and innovation, while some telehealth players claim to expand access. How the FDA uses enforcement discretion or litigation unfolds will affect telehealth compounding business models and the market for oral GLP‑1 alternatives.